<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>JW (Cayman) Therapeutics Co. Ltd.（(HK:2126)）刚刚发布了一项公告。</p>
<p>JW (Cayman) Therapeutics Co. Ltd. 宣布了其董事会的组成，强调了每位成员的角色和职能。董事会由非执行董事和独立非执行董事组成，特定成员在审计、薪酬、提名以及业务发展和战略委员会等各个委员会中担任职务。此公告具有重要意义，因为它概述了公司的治理结构和战略监督，可能影响其运营和战略方向。</p>
<p>（HK:2126）股票的最新分析师评级为持有，目标价格为 HK$3.00。要查看 JW (Cayman) Therapeutics Co. Ltd. 股票的完整分析师预测列表，请访问 HK:2126 股票预测页面。</p>
<p><strong>关于 JW (Cayman) Therapeutics Co. Ltd. 的更多信息</strong></p>
<p>JW (Cayman) Therapeutics Co. Ltd. 是一家注册于开曼群岛的生物技术公司，专注于创新细胞治疗的开发。该公司在医疗行业运营，提供旨在治疗各种疾病的先进治疗解决方案。</p>
<p><strong>平均交易量：</strong> 2,092,405</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> HK$1.29B</p>
<p>要对 2126 股票进行全面评估，请访问 TipRanks 的股票分析页面。</p>

药明巨诺-B

<p>JW Therapeutics 宣布了其董事会组成，详细说明了非执行董事和独立董事的角色和职能。成员们在审计、薪酬、提名以及业务发展和战略等委员会中任职。这一治理结构影响公司的战略方向。分析师对 JW 股票（HK:2126）的评级为持有，目标价为 3.00 港元。JW Therapeutics 专注于医疗保健领域的创新细胞治疗</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) just unveiled an announcement.</p>
<div class="lb-trans"><p>JW (Cayman) Therapeutics Co. Ltd.（(HK:2126)）刚刚发布了一项公告。</p>
</div><p>JW (Cayman) Therapeutics Co. Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board comprises non-executive and independent non-executive directors, with specific members serving on various committees, such as the Audit, Remuneration, Nomination, and Business Development and Strategy Committees. This announcement is significant as it outlines the governance structure and strategic oversight within the company, potentially impacting its operational and strategic direction.</p>
<div class="lb-trans"><p>JW (Cayman) Therapeutics Co. Ltd. 宣布了其董事会的组成，强调了每位成员的角色和职能。董事会由非执行董事和独立非执行董事组成，特定成员在审计、薪酬、提名以及业务发展和战略委员会等各个委员会中担任职务。此公告具有重要意义，因为它概述了公司的治理结构和战略监督，可能影响其运营和战略方向。</p>
</div><p>The most recent analyst rating on (HK:2126) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.</p>
<div class="lb-trans"><p>（HK:2126）股票的最新分析师评级为持有，目标价格为 HK$3.00。要查看 JW (Cayman) Therapeutics Co. Ltd. 股票的完整分析师预测列表，请访问 HK:2126 股票预测页面。</p>
</div><p><strong>More about JW (Cayman) Therapeutics Co. Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 JW (Cayman) Therapeutics Co. Ltd. 的更多信息</strong></p>
</div><p>JW (Cayman) Therapeutics Co. Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development of innovative cell-based therapies. The company operates in the healthcare industry, providing advanced therapeutic solutions aimed at treating various diseases.</p>
<div class="lb-trans"><p>JW (Cayman) Therapeutics Co. Ltd. 是一家注册于开曼群岛的生物技术公司，专注于创新细胞治疗的开发。该公司在医疗行业运营，提供旨在治疗各种疾病的先进治疗解决方案。</p>
</div><p><strong>Average Trading Volume:</strong> 2,092,405</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 2,092,405</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$1.29B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> HK$1.29B</p>
</div><p>For a thorough assessment of 2126 stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要对 2126 股票进行全面评估，请访问 TipRanks 的股票分析页面。</p>
</div>

药明巨诺-B 宣布董事会的组成及其角色